This research area aims at creating capabilities for discovery and validation of diagnostic, predictive, prognostic and therapeutic biomarkers. In addition, building capabilities for systems immunology and systems virologi of COVID-19 infected patients, as well as concepts towards individualized monitoring and targeting of cytokine storms are also part of the aim.
This area consists of 6 individual projects, funded a total of 6,6 MSEK. Led by researchers at KTH Royal Institute of Technology, Karolinska Institutet, University of Gothenburg, Lund University and Linköping University.
Coordinator: David Gotthold, KTH Royal Institute of Technology
Identification of plasma biomarkers for risk stratification of hospitalised Covid-19 patients
Jacob Odeberg, KTH
Prediction of severe disease in Covid-19
Lars-Magnus Andersson, University of Gothenburg
Taking back the control of the SARS-CoV2 antiviral immune response as a mean to neutralize the COVID19 disease pathogenicity
Marie Larsson, Linköping University
Systems immunology analyses of the cytokine storm in COVID-19
Petter Brodin, Karolinska Institutet
Establishing a biobank of clinical specimens for studying evolution of viral diversity and development of immune response, including inflammation, seroprevalence and protective antibodies, in SARS-Cov2 infection (Research project)
Patrik Medstrand, Lund University
Dynamics and longevity of the specific adaptive immune response in COVID-19 patients
Davide Angeletti, University of Gothenburg
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.